MoonLake (MLTX) | Stock Overview & Key Data
MoonLake Performance Comparison
Stock Range
Today's Range
Low: $8.53
High: $9.52
on October 6, 2025
52 Week Range
Low: $5.95
High: $62.75
on September 29, 2025
on September 26, 2025
All-Time High: $64.98 on February 12, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$535.3M
EPS
-2.79
P/E Ratio (TTM)
-4.46
Forward P/E
-3.36
P/B Ratio
1.51
PEG Ratio
-0.04
Div. Yield
N/A
ROE
-40.34%
Beta
1.098
Debt to Equity
21.17
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
0.00%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-24.99%
Return on Equity (TTM)
-40.34%
EBITDA
$-199.0M
Net Income (TTM)
$-176.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
N/A
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
N/A
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| MoonLake MLTX | 535.32M Small-cap | 38.78% | -85.83% | -81.77% | -75.10% | -83.83% | -82.30% | -1.59% | -17.99% |
| Vertex VRTX | 103.40B Large-cap | 1.92% | 1.94% | -12.30% | -15.10% | -0.70% | -16.36% | 37.41% | 84.75% |
| Regeneron REGN | 63.78B Large-cap | 4.41% | 4.84% | 8.80% | 2.22% | -18.14% | -42.36% | -20.46% | -2.38% |
| Vera Therapeutics VERA | 1.98B Small-cap | 7.06% | 25.01% | 34.70% | 55.17% | -26.68% | -27.57% | 61.31% | 169.04% |
| Dyne Therapeutics DYN | 1.95B Small-cap | 2.26% | -4.89% | 54.65% | 68.89% | -50.31% | -62.43% | -4.09% | -27.38% |
| Liquidia LQDA | 1.93B Small-cap | 0.26% | -18.30% | 83.61% | 83.91% | 88.93% | 106.13% | 328.89% | 699.30% |
Ownership & Short Interest
Insider Ownership
11.02%
Institutional Ownership
95.06%
Shares Short
5M
Short Ratio
7.90
Short % of Shares Outstanding
17.48%
Average 10-Day Volume
16M
Average 90-Day Volume
6M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is MLTX's 52-week high and low?
- In the last 52 weeks, MoonLake reached a high of $62.75 (on September 26, 2025) and a low of $5.95 (on September 29, 2025).
- What is the market cap and P/E ratio for MLTX?
- Curious about MoonLake's size and valuation? Its market capitalization stands at 535.32M. When it comes to valuation, the P/E ratio (trailing twelve months) is -4.46, and the forward P/E (looking ahead) is -3.36.
- Does MLTX pay dividends? If so, what's the yield?
- As for dividends, MoonLake isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are MoonLake's main competitors or similar companies to consider before investing?
When looking at MoonLake, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX103.40B Healthcare Biotechnology -16.36% 37.41% Regeneron
REGN63.78B Healthcare Biotechnology -42.36% -20.46% Vera Therapeutics
VERA1.98B Healthcare Biotechnology -27.57% 61.31% Dyne Therapeutics
DYN1.95B Healthcare Biotechnology -62.43% -4.09% Liquidia
LQDA1.93B Healthcare Biotechnology 106.13% 328.89% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for MoonLake Immunotherapeutics? (e.g., ROE, Debt/Equity)
- To get a sense of MoonLake's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -40.34%, the Debt to Equity ratio from the most recent quarter is 21.17, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for MLTX?
- Looking at MoonLake's growth, its revenue over the trailing twelve months (TTM) was $0. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.
- How much of MLTX stock is held by insiders and institutions?
- Wondering who owns MoonLake stock? Company insiders (like executives and directors) hold about 11.02% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 95.06%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.